Targeted nanoparticles for early diagnosis and treatment of bladder Cancer
Market Maturity: Business Ready
These are innovations that are putting concrete market-oriented ideas together and are, for example, pursuing market studies, business plans, engagements with relevant partner and end-users. Learn more
Market Creation Potential
This innovation was assessed by the JRC’s Market Creation Potential indicator framework as having a “Very high” level of Market Creation Potential. Only innovations that are showing multiple signals of market creation potential are assigned a value under this indicator system. Learn more
Go to Market needs
Needs that, if addressed, can increase the chances this innovation gets to (or closer to) the market incude:
Prepare for Market entry
Scale-up market opportunities
Location of Key Innovators developing this innovation
LIME TECHNOLOGY IKE
IOANNINA, GR Small or Medium Enterprise
OSPEDALE SAN RAFFAELE SRL
MILANO, IT Large Enterprise
ALMA MATER STUDIORUM - UNIVERSITA DI BOLOGNA
BOLOGNA, IT Higher Education Institute / Research Centre
The EU-funded Research Project
This innovation was developed under the Horizon 2020 project EDIT with an end date of 30/09/2022
Unmet clinical needs in the management of bladder cancer (BCa) are the prevention of tumor onset, relapse and progression, and therapy of the aggressive carcinoma in situ (Cis), requiring weekly treatments and endless follow-up, with a consequent poor quality of life and the highest cost per patient among all cancers. Therefore, public health programs crave for early BCa detection protocols, to improve performance in the management of this devastating disease. Here we propose an advanced transformative technology termed EDIT combining a novel high-resolution ultrasound elastography and photoacoustic imaging on the bladder instilled with targeted plasmonic gold sensors.
EDIT approach exploits the structural and mechanical properties of the bladder extracellular matrix (ECM) as a unique biomarker of the early onset/progression/relapse of carcinoma, through engineered novel gold nanorods (GNRs) used as intravesical photoacoustic antennas targeted at the ECM, generating an ad hoc visualization platform. GNRs will be further utilized as heat-releasing effectors at nanoscale for targeted cancer photo-thermal therapy. EDIT is designed to detect pre-neoplastic area and eradication of local areas at few cells resolution with high sensitivity and specificity.
We bring together a multi and transdisciplinary consortium capable to develop non-invasive and non-ionizing novel technology and preclinical validation for early prognosis of BCa and therapeutic nanomedicine against bladder Cis. Outcomes of EDIT will revolutionize the management of BCa with the introduction of sensing and effector nanotechnologies combined with non-invasive organ imaging with high resolution/definition by 3D ultrasound and photoacoustic imaging.
Structural and mechanical modification of the ECM is a common denominator for invasive breast, colorectal, prostate and bladder cancers. EDIT platforms will also pave the ways for the earlier management of other bladder-related pathologies and solid tumors.
Innnovation Radar's analysis of this innovation is based on data collected on 16/12/2019.